Article

Ads tout ICLs

Coming soon to a theater, cable television station, or network television station near you: five commercials touting the benefits of a proprietary implantable contact lens ([ICL] Visian ICL, STAAR Surgical Co.) over contact lenses and glasses.

Monrovia, CA-Coming soon to a theater, cable television station, or network television station near you: five commercials touting the benefits of a proprietary implantable contact lens (ICL) (Visian ICL, STAAR Surgical Co.) over contact lenses and glasses.

The ads represent the second phase of the company’s direct-to-consumer campaign. This phase includes commercials in movie theaters in Century City, CA, Phoenix, and Houston, which began March 18. The movie theater portion of the campaign also includes in-lobby promotions, consumer brochures, and partnerships with surgeons in each market who will be offering a $1,000 discount on implantation procedures.

In the Santa Barbara, CA, area, Paul Dougherty, MD, will be airing the commercials on cable television for 4 months beginning in April.

“Initial customer feedback from the first phase of the campaign was very positive, and we learned better the messages that resonated best with our surgeons and potential patients,” said Barry G. Caldwell, president and chief executive officer of STAAR Surgical. “We expect to learn even more during this second phase by further testing and fine-tuning our message to consumers as we intend to expand in a very prudent way into additional key markets.”

The new commercials are similar to ads that appeared on various Web sites during the first phase of the campaign. All commercials are viewable at www .SeeGreatNow.com, where consumers also can print a coupon for the discounted procedure and locate a surgeon to perform it.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.